Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07563894 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT07563894 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.
The verdict
NCT07563894, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability (rBA) of the Form 2 film-coated tablet of PF-07799933 intended for use in future studies compared to the current Form 1 tablet of PF-07799933 used in Phase 1 studies. Additionally this study will also evaluate the effect of a high-fat meal on the plasma pharmacokinetics (PK), i.e, the rBA compared to overnight fasting, of PF-07799933 and PF-07799544 following concurrent single-dose oral administration of Form 2 film-coated tablet formulation of PF-07799933 with PF-07799544. Finally, this study will also assess the impact of a proton pump inhibitor (a type of acid reducing agent) on PF-07799933 PK of the Form 2 film-coated tablet formulation. These data will be used to inform administration of PF-07799933 and PF-07799544 with food and acid reducing agents in future clinical trials.
Interventions
- DRUG PF-07799933 tablets with PF-07799544 fasted
- DRUG PF-07799933 film-coated tablets with PF-07799544 fasted
- DRUG PF-07799933 film-coated tablets with PF-07799544 fed
- DRUG PF-07799933 film-coated tablets fasted
- DRUG PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2026-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07563894
The ClinicalTrials.gov registry entry for NCT07563894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which PF-07799933 tablets with PF-07799544 fasted is the first listed.
NCT07563894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07563894 about?
NCT07563894 is a clinical study titled "Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544". The purpose of this study is to evaluate the relative bioavailability (rBA) of the Form 2 film-coated tablet of PF-07799933 intended for use in future studies compared to the current Form 1 tablet of PF-07799933 used in Phase 1 studies. Additionally this study will also evaluate the effect of a high...
What is the current status of trial NCT07563894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2026-04-10. Estimated completion is 2026-06-26.
What interventions are being tested in trial NCT07563894?
The interventions under investigation include: PF-07799933 tablets with PF-07799544 fasted (DRUG), PF-07799933 film-coated tablets with PF-07799544 fasted (DRUG), PF-07799933 film-coated tablets with PF-07799544 fed (DRUG), PF-07799933 film-coated tablets fasted (DRUG), PF-07799933 film-coated tablets following rabeprazole pretreatment fasted (DRUG).
Who is sponsoring clinical trial NCT07563894?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.